Cargando…
The Cost-Effectiveness of Supplemental Carnosine in Type 2 Diabetes
In this paper, we assess the cost-effectiveness of 1 g daily of carnosine (an over the counter supplement) in addition to standard care for the management of type 2 diabetes and compare it to standard care alone. Dynamic multistate life table models were constructed in order to estimate both clinica...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8747040/ https://www.ncbi.nlm.nih.gov/pubmed/35011089 http://dx.doi.org/10.3390/nu14010215 |
_version_ | 1784630734350188544 |
---|---|
author | Menon, Kirthi de Courten, Barbora Magliano, Dianna J. Ademi, Zanfina Liew, Danny Zomer, Ella |
author_facet | Menon, Kirthi de Courten, Barbora Magliano, Dianna J. Ademi, Zanfina Liew, Danny Zomer, Ella |
author_sort | Menon, Kirthi |
collection | PubMed |
description | In this paper, we assess the cost-effectiveness of 1 g daily of carnosine (an over the counter supplement) in addition to standard care for the management of type 2 diabetes and compare it to standard care alone. Dynamic multistate life table models were constructed in order to estimate both clinical outcomes and costs of Australians aged 18 years and above with and without type 2 diabetes over a ten-year period, 2020 to 2029. The dynamic nature of the model allowed for population change over time (migration and deaths) and accounted for the development of new cases of diabetes. The three health states were ‘Alive without type 2 diabetes’, ‘Alive with type 2 diabetes’ and ‘Dead’. Transition probabilities, costs, and utilities were obtained from published sources. The main outcome of interest was the incremental cost-effectiveness ratio (ICER) in terms of cost per year of life saved (YoLS) and cost per quality-adjusted life year (QALY) gained. Over the ten-year period, the addition of carnosine to standard care treatment resulted in ICERs (discounted) of AUD 34,836 per YoLS and AUD 43,270 per QALY gained. Assuming the commonly accepted willingness to pay threshold of AUD 50,000 per QALY gained, supplemental dietary carnosine may be a cost-effective treatment option for people with type 2 diabetes in Australia. |
format | Online Article Text |
id | pubmed-8747040 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-87470402022-01-11 The Cost-Effectiveness of Supplemental Carnosine in Type 2 Diabetes Menon, Kirthi de Courten, Barbora Magliano, Dianna J. Ademi, Zanfina Liew, Danny Zomer, Ella Nutrients Article In this paper, we assess the cost-effectiveness of 1 g daily of carnosine (an over the counter supplement) in addition to standard care for the management of type 2 diabetes and compare it to standard care alone. Dynamic multistate life table models were constructed in order to estimate both clinical outcomes and costs of Australians aged 18 years and above with and without type 2 diabetes over a ten-year period, 2020 to 2029. The dynamic nature of the model allowed for population change over time (migration and deaths) and accounted for the development of new cases of diabetes. The three health states were ‘Alive without type 2 diabetes’, ‘Alive with type 2 diabetes’ and ‘Dead’. Transition probabilities, costs, and utilities were obtained from published sources. The main outcome of interest was the incremental cost-effectiveness ratio (ICER) in terms of cost per year of life saved (YoLS) and cost per quality-adjusted life year (QALY) gained. Over the ten-year period, the addition of carnosine to standard care treatment resulted in ICERs (discounted) of AUD 34,836 per YoLS and AUD 43,270 per QALY gained. Assuming the commonly accepted willingness to pay threshold of AUD 50,000 per QALY gained, supplemental dietary carnosine may be a cost-effective treatment option for people with type 2 diabetes in Australia. MDPI 2022-01-04 /pmc/articles/PMC8747040/ /pubmed/35011089 http://dx.doi.org/10.3390/nu14010215 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Menon, Kirthi de Courten, Barbora Magliano, Dianna J. Ademi, Zanfina Liew, Danny Zomer, Ella The Cost-Effectiveness of Supplemental Carnosine in Type 2 Diabetes |
title | The Cost-Effectiveness of Supplemental Carnosine in Type 2 Diabetes |
title_full | The Cost-Effectiveness of Supplemental Carnosine in Type 2 Diabetes |
title_fullStr | The Cost-Effectiveness of Supplemental Carnosine in Type 2 Diabetes |
title_full_unstemmed | The Cost-Effectiveness of Supplemental Carnosine in Type 2 Diabetes |
title_short | The Cost-Effectiveness of Supplemental Carnosine in Type 2 Diabetes |
title_sort | cost-effectiveness of supplemental carnosine in type 2 diabetes |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8747040/ https://www.ncbi.nlm.nih.gov/pubmed/35011089 http://dx.doi.org/10.3390/nu14010215 |
work_keys_str_mv | AT menonkirthi thecosteffectivenessofsupplementalcarnosineintype2diabetes AT decourtenbarbora thecosteffectivenessofsupplementalcarnosineintype2diabetes AT maglianodiannaj thecosteffectivenessofsupplementalcarnosineintype2diabetes AT ademizanfina thecosteffectivenessofsupplementalcarnosineintype2diabetes AT liewdanny thecosteffectivenessofsupplementalcarnosineintype2diabetes AT zomerella thecosteffectivenessofsupplementalcarnosineintype2diabetes AT menonkirthi costeffectivenessofsupplementalcarnosineintype2diabetes AT decourtenbarbora costeffectivenessofsupplementalcarnosineintype2diabetes AT maglianodiannaj costeffectivenessofsupplementalcarnosineintype2diabetes AT ademizanfina costeffectivenessofsupplementalcarnosineintype2diabetes AT liewdanny costeffectivenessofsupplementalcarnosineintype2diabetes AT zomerella costeffectivenessofsupplementalcarnosineintype2diabetes |